Orexigen Therapeutics, Inc. (NASDAQ:OREX)’s Long-Awaited Obesity Pill Contrave Received FDA Nod

Boston, MA 09/12/2014 (wallstreetpr) – The U.S. Food and Drug Administration gave a green signal to Orexigen Therapeutics, Inc. (NASDAQ:OREX) diet pill called Contrave for sale in the country. The reason why this approval holds prominence is because it is the only third kind of obesity treatment/pill in over 10 years, which has received FDA’s […]

Why Orexigen Therapeutics, Inc. (NASDAQ:OREX) May Ride Smooth In Tricky Weight-Drug Market

Boston, MA 06/11/2014 (wallstreetpr) – Orexigen Therapeutics, Inc. (NASDAQ:OREX) intends to bring its obesity drug called Contrave to the market after the U.S. Food and Drug Administration issues its verdict today. The approval of the drug will be a milestone for the company given its many past challenges to bring the drug to the market. […]